Pictet Asset Management Holding SA Lowers Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Pictet Asset Management Holding SA lowered its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 11.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 354,455 shares of the biopharmaceutical company’s stock after selling 46,394 shares during the period. Pictet Asset Management Holding SA’s holdings in Agios Pharmaceuticals were worth $11,647,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Venturi Wealth Management LLC purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $33,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $53,000. KBC Group NV increased its holdings in shares of Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 611 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at $146,000. Finally, AlphaQuest LLC boosted its holdings in Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 2,338 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts have weighed in on AGIO shares. Scotiabank lifted their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 target price for the company. Finally, Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals presently has an average rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $28.44 on Thursday. Agios Pharmaceuticals, Inc. has a 1 year low of $26.66 and a 1 year high of $62.58. The firm has a market capitalization of $1.63 billion, a PE ratio of 2.51 and a beta of 0.90. The business’s 50 day moving average price is $32.88 and its 200-day moving average price is $40.49.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. The trade was a 12.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.